{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T18:14:14Z","timestamp":1794680054496,"version":"4.9.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To evaluate the clinical outcomes of patients who received stereotactic body radiation therapy (SBRT) for single viable hepatocellular carcinoma (HCC) at the site of incomplete transarterial chemoembolization (TACE).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients treated with SBRT for single viable HCC after incomplete TACE between 2012 and 2017 at Asan Medical Center (Seoul, South Korea) were included. Incomplete TACE was defined as (1) evidence of viable HCC at the site of TACE on follow-up dynamic computed tomography (CT) or magnetic resonance imaging following one or more consecutive TACEs, (2) no definite tumor staining on superselective hepatic angiogram, or (3) no definite iodized oil uptake on post-embolization angiogram or CT. Doses of 10\u201315\u2009Gy per fraction were given over 3\u20134 consecutive days. The primary outcome was local control rate at 3\u2009years and secondary outcome included tumor response, overall survival rate, out-of-field intrahepatic recurrence-free survival, distant metastasis-free survival and treatment-related toxicities. Treatment-related adverse events were evaluated according to the common terminology criteria for adverse events, version 4.03.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 302 patients were analyzed. The median follow-up duration was 32.9\u2009months (interquartile range [IQR], 23.6\u201341.7) and the median tumor size was 2.0\u2009cm (range, 0.7\u20136.9). The local control (LC) and overall survival rates at 3\u2009years were 91.2 and 72.7%, respectively. 95.4% of the tumors reached complete response (CR) during the entire follow-up period (anyCR). The median interval from SBRT to anyCR was 3.4\u2009months (IQR, 1.9\u20134.7), and 39.9 and 83.3% of the lesions reached CR at 3- and 6-months after SBRT, respectively. Radiation-induced liver disease was observed in 8 (2.6%) patients. No patients experienced gastroduodenal bleeding within the radiation field.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>SBRT could be considered a feasible salvage treatment option for HCC after incomplete TACE.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-09263-3","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T06:03:57Z","timestamp":1644991437000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: a retrospective analysis of 302 patients"],"prefix":"10.1186","volume":"22","author":[{"given":"Sumin","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7034-8454","authenticated-orcid":false,"given":"Jinhong","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-hong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonggi","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danbi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Hyun","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang Mo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Suk","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Chu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Hyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Min","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,16]]},"reference":[{"issue":"6","key":"9263_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"9263_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3350\/cmh.2017.0112","volume":"24","author":"BH Kim","year":"2018","unstructured":"Kim BH, Park JW. Epidemiology of liver cancer in South Korea. Clin Mol Hepatol. 2018;24(1):1\u20139.","journal-title":"Clin Mol Hepatol."},{"issue":"10127","key":"9263_CR3","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301\u201314.","journal-title":"Lancet."},{"issue":"9319","key":"9263_CR4","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","volume":"359","author":"JM Llovet","year":"2002","unstructured":"Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734\u20139.","journal-title":"Lancet."},{"issue":"5","key":"9263_CR5","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","volume":"35","author":"CM Lo","year":"2002","unstructured":"Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164\u201371.","journal-title":"Hepatology."},{"issue":"9","key":"9263_CR6","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1111\/liv.12818","volume":"35","author":"JW Park","year":"2015","unstructured":"Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study. Liver Int. 2015;35(9):2155\u201366.","journal-title":"Liver Int"},{"issue":"5","key":"9263_CR7","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.3348\/kjr.2015.16.5.1068","volume":"16","author":"HJ Kang","year":"2015","unstructured":"Kang HJ, Kim YI, Kim HC, Jae HJ, Hur S, Chung JW. Does establishing a safety margin reduce local recurrence in subsegmental Transarterial chemoembolization for small nodular hepatocellular carcinomas? Korean J Radiol. 2015;16(5):1068\u201378.","journal-title":"Korean J Radiol"},{"issue":"1","key":"9263_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1148\/radiology.188.1.8390073","volume":"188","author":"O Matsui","year":"1993","unstructured":"Matsui O, Kadoya M, Yoshikawa J, Gabata T, Arai K, Demachi H, et al. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology. 1993;188(1):79\u201383.","journal-title":"Radiology."},{"issue":"3","key":"9263_CR9","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jvir.2006.12.004","volume":"18","author":"S Miyayama","year":"2007","unstructured":"Miyayama S, Matsui O, Yamashiro M, Ryu Y, Kaito K, Ozaki K, et al. Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil. J Vasc Interv Radiol. 2007;18(3):365\u201376.","journal-title":"J Vasc Interv Radiol"},{"issue":"5","key":"9263_CR10","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1002\/hep.24246","volume":"53","author":"R Golfieri","year":"2011","unstructured":"Golfieri R, Cappelli A, Cucchetti A, Piscaglia F, Carpenzano M, Peri E, et al. Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas. Hepatology. 2011;53(5):1580\u20139.","journal-title":"Hepatology."},{"issue":"6","key":"9263_CR11","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.ejrad.2011.03.046","volume":"81","author":"I Bargellini","year":"2012","unstructured":"Bargellini I, Sacco R, Bozzi E, Bertini M, Ginanni B, Romano A, et al. Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort study. Eur J Radiol. 2012;81(6):1173\u20138.","journal-title":"Eur J Radiol"},{"issue":"6","key":"9263_CR12","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.jhep.2012.07.025","volume":"57","author":"E Terzi","year":"2012","unstructured":"Terzi E, Golfieri R, Piscaglia F, Galassi M, Dazzi A, Leoni S, et al. Response rate and clinical outcome of HCC after first and repeated cTACE performed \"on demand\". J Hepatol. 2012;57(6):1258\u201367.","journal-title":"J Hepatol"},{"issue":"21","key":"9263_CR13","doi-asserted-by":"publisher","first-page":"5424","DOI":"10.1002\/cncr.27533","volume":"118","author":"JK Kang","year":"2012","unstructured":"Kang JK, Kim MS, Cho CK, Yang KM, Yoo HJ, Kim JH, et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer. 2012;118(21):5424\u201331.","journal-title":"Cancer."},{"issue":"11","key":"9263_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0079854","volume":"8","author":"SM Yoon","year":"2013","unstructured":"Yoon SM, Lim YS, Park MJ, Kim SY, Cho B, Shim JH, et al. Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma. PLoS One. 2013;8(11):e79854.","journal-title":"PLoS One"},{"issue":"4","key":"9263_CR15","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/j.ijrobp.2011.04.011","volume":"81","author":"DL Andolino","year":"2011","unstructured":"Andolino DL, Johnson CS, Maluccio M, Kwo P, Tector AJ, Zook J, et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2011;81(4):e447\u201353.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"13","key":"9263_CR16","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1200\/JCO.2012.44.1659","volume":"31","author":"A Bujold","year":"2013","unstructured":"Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013;31(13):1631\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"9263_CR17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jamaoncol.2017.2303","volume":"4","author":"M Feng","year":"2018","unstructured":"Feng M, Suresh K, Schipper MJ, Bazzi L, Ben-Josef E, Matuszak MM, et al. Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage: a phase 2 clinical trial. JAMA Oncol. 2018;4(1):40\u20137.","journal-title":"JAMA Oncol"},{"issue":"6","key":"9263_CR18","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1159\/000509424","volume":"9","author":"J Zhou","year":"2020","unstructured":"Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition). Liver Cancer. 2020;9(6):682\u2013720.","journal-title":"Liver Cancer."},{"issue":"4","key":"9263_CR19","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1159\/000475768","volume":"6","author":"ZC Zeng","year":"2017","unstructured":"Zeng ZC, Seong J, Yoon SM, Cheng JC, Lam KO, Lee AS, et al. Consensus on stereotactic body radiation therapy for small-sized hepatocellular carcinoma at the 7th Asia-Pacific primary liver Cancer expert meeting. Liver Cancer. 2017;6(4):264\u201374.","journal-title":"Liver Cancer."},{"issue":"2","key":"9263_CR20","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and Management of Hepatocellular Carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723\u201350.","journal-title":"Hepatology."},{"issue":"3","key":"9263_CR21","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.24199","volume":"53","author":"J Bruix","year":"2011","unstructured":"Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020\u20132.","journal-title":"Hepatology."},{"issue":"1","key":"9263_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3350\/cmh.2018.0065","volume":"26","author":"JS Lee","year":"2020","unstructured":"Lee JS, Kim BK, Kim SU, Park JY, Ahn SH, Seong JS, et al. A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea. Clin Mol Hepatol. 2020;26(1):24\u201332.","journal-title":"Clin Mol Hepatol"},{"issue":"3-4","key":"9263_CR23","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1159\/000343875","volume":"3","author":"M Kudo","year":"2014","unstructured":"Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, et al. JSH consensus-based clinical practice guidelines for the Management of Hepatocellular Carcinoma: 2014 update by the liver Cancer study Group of Japan. Liver Cancer. 2014;3(3-4):458\u201368.","journal-title":"Liver Cancer"},{"issue":"1","key":"9263_CR24","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52\u201360.","journal-title":"Semin Liver Dis"},{"issue":"5","key":"9263_CR25","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/j.ijrobp.2011.03.019","volume":"82","author":"SM Yoon","year":"2012","unstructured":"Yoon SM, Lim YS, Won HJ, Kim JH, Kim KM, Lee HC, et al. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. Int J Radiat Oncol Biol Phys. 2012;82(5):2004\u201311.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"9263_CR26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.radonc.2019.08.009","volume":"141","author":"YJ Kim","year":"2019","unstructured":"Kim YJ, Jung J, Joo JH, Kim SY, Kim JH, Lim YS, et al. Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: necessity to subclassify Barcelona clinic liver Cancer stage C. Radiother Oncol. 2019;141:95\u2013100.","journal-title":"Radiother Oncol"},{"issue":"3","key":"9263_CR27","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.jvir.2014.10.019","volume":"26","author":"GA Kim","year":"2015","unstructured":"Kim GA, Shim JH, Yoon SM, Jung J, Kim JH, Ryu MH, et al. Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. J Vasc Interv Radiol. 2015;26(3):320\u20139.e6.","journal-title":"J Vasc Interv Radiol"},{"issue":"5","key":"9263_CR28","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.3390\/cancers12051116","volume":"12","author":"HH Chu","year":"2020","unstructured":"Chu HH, Kim JH, Shim JH, Yoon SM, Kim PH, Alrashidi I. Chemoembolization plus radiotherapy versus chemoembolization plus Sorafenib for the treatment of hepatocellular carcinoma invading the portal vein: a propensity score matching analysis. Cancers (Basel). 2020;12(5):1116.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"9263_CR29","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1186\/s12885-018-4340-7","volume":"18","author":"Y Jeong","year":"2018","unstructured":"Jeong Y, Jung J, Cho B, Kwak J, Jeong C, Kim JH, et al. Stereotactic body radiation therapy using a respiratory-gated volumetric-modulated arc therapy technique for small hepatocellular carcinoma. BMC Cancer. 2018;18(1):416.","journal-title":"BMC Cancer"},{"issue":"3 Suppl","key":"9263_CR30","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1016\/j.ijrobp.2009.06.092","volume":"76","author":"CC Pan","year":"2010","unstructured":"Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S94\u2013100.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"9263_CR31","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.ijrobp.2005.01.002","volume":"62","author":"TE Schefter","year":"2005","unstructured":"Schefter TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A, Gaspar LE. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys. 2005;62(5):1371\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3 Suppl","key":"9263_CR32","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.ijrobp.2009.07.1754","volume":"76","author":"LB Marks","year":"2010","unstructured":"Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S10\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"9263_CR33","doi-asserted-by":"publisher","first-page":"01TR","DOI":"10.1088\/1361-6560\/aaf26a","volume":"64","author":"SJ McMahon","year":"2018","unstructured":"McMahon SJ. The linear quadratic model: usage, interpretation and challenges. Phys Med Biol. 2018;64(1):01TR.","journal-title":"Phys Med Biol"},{"issue":"9822","key":"9263_CR34","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0140-6736(11)61347-0","volume":"379","author":"A Forner","year":"2012","unstructured":"Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245\u201355.","journal-title":"Lancet."},{"issue":"1","key":"9263_CR35","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the liver","year":"2018","unstructured":"European Association for the Study of the liver. Electronic address eee, European Association for the Study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182\u2013236.","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"9263_CR36","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1159\/000368149","volume":"87","author":"K Yamakado","year":"2014","unstructured":"Yamakado K, Kudo M. Treatment strategies of intermediate-stage hepatocellular carcinomas in Japan (Barcelona clinic liver Cancer stage B). Oncology. 2014;87(Suppl 1):78\u201381.","journal-title":"Oncology."},{"issue":"10","key":"9263_CR37","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/hepr.13411","volume":"49","author":"N Kokudo","year":"2019","unstructured":"Kokudo N, Takemura N, Hasegawa K, Takayama T, Kubo S, Shimada M, et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res. 2019;49(10):1109\u201313.","journal-title":"Hepatol Res"},{"key":"9263_CR38","doi-asserted-by":"publisher","first-page":"S202","DOI":"10.1016\/S0167-8140(21)00397-2","volume":"152","author":"T Comito","year":"2020","unstructured":"Comito T, Loi M, Franzese C, Clerici E, Pedicini V, Poretti D, et al. OC-0373: SBRT versus TAE\/TACE in hepatocellular carcinoma: results from a phase III trial (NCT02323360). Radiother Oncol. 2020;152:S202\u2013S3.","journal-title":"Radiother Oncol"},{"issue":"13","key":"9263_CR39","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1002\/cncr.30008","volume":"122","author":"A Takeda","year":"2016","unstructured":"Takeda A, Sanuki N, Tsurugai Y, Iwabuchi S, Matsunaga K, Ebinuma H, et al. Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation. Cancer. 2016;122(13):2041\u20139.","journal-title":"Cancer."},{"issue":"3","key":"9263_CR40","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3109\/0284186X.2013.820342","volume":"53","author":"N Sanuki","year":"2014","unstructured":"Sanuki N, Takeda A, Oku Y, Mizuno T, Aoki Y, Eriguchi T, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients. Acta Oncol. 2014;53(3):399\u2013404.","journal-title":"Acta Oncol"},{"issue":"2","key":"9263_CR41","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.radonc.2015.04.006","volume":"115","author":"A Huertas","year":"2015","unstructured":"Huertas A, Baumann AS, Saunier-Kubs F, Salleron J, Oldrini G, Croise-Laurent V, et al. Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinoma. Radiother Oncol. 2015;115(2):211\u20136.","journal-title":"Radiother Oncol"},{"key":"9263_CR42","doi-asserted-by":"crossref","unstructured":"Kubo K, Kimura T, Aikata H, Takahashi S, Takeuchi Y, Takahashi I, et al. Long-term outcome of stereotactic body radiotherapy for patients with small hepatocellular carcinoma. Hepatol Res. 2018;48(9):701-7.","DOI":"10.1111\/hepr.13063"},{"issue":"4","key":"9263_CR43","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.ijrobp.2017.08.022","volume":"102","author":"M Mendiratta-Lala","year":"2018","unstructured":"Mendiratta-Lala M, Gu E, Owen D, Cuneo KC, Bazzi L, Lawrence TS, et al. Imaging findings within the first 12 months of hepatocellular carcinoma treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2018;102(4):1063\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"9263_CR44","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ijrobp.2018.09.004","volume":"103","author":"M Mendiratta-Lala","year":"2019","unstructured":"Mendiratta-Lala M, Masch W, Shankar PR, Hartman HE, Davenport MS, Schipper MJ, et al. Magnetic resonance imaging evaluation of hepatocellular carcinoma treated with stereotactic body radiation therapy: long term imaging follow-up. Int J Radiat Oncol Biol Phys. 2019;103(1):169\u201379.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"9263_CR45","doi-asserted-by":"crossref","unstructured":"Yoon SM, Kim SY, Lim YS, Kim KM, Shim JH, Lee D, et al. Stereotactic body radiation therapy for small (<\/=5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial. Clin Mol Hepatol. 2020.","DOI":"10.3350\/cmh.2020.0038"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09263-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-09263-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09263-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T10:03:40Z","timestamp":1666346620000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-09263-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,16]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["9263"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-09263-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,16]]},"assertion":[{"value":"28 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was approved by the Institutional Review Board of Asan Medical Center (IRB no. 2018-1004) and all methods were performed in accordance with the relevant guidelines and regulations. As this study was a retrospective analysis, a waiver of the requirement for informed consent was granted by the Institutional Review Board of Asan Medical Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"175"}}